-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
This article summarizes the consensus on the domestic and foreign liver disease related guidelines issued in the first half of 2021, for everyone to read and download! (PS: Contains guidelines and consensus with the title of the 2020 version but only officially finalized in 2021) The consensus on the secondary prevention of primary liver cancer (2021 version) In order to standardize the effective prevention, early screening and diagnosis of people at risk of primary liver cancer, The Hepatology Branch of the Chinese Medical Association organized relevant domestic experts to formulate the "Primary Liver Cancer II" based on the research progress of the etiology, pathogenesis, diagnostic technology, prevention and treatment of primary liver cancer at home and abroad, especially the research results adapted to China’s national conditions.
Consensus on Level Prevention (2021 Edition)
.
This consensus mainly includes the risk factors, monitoring and screening, early diagnosis and prevention of primary liver cancer in the population of chronic liver disease in China
.
Download link: http://guide.
medlive.
cn/guideline/22780 Recommended reading: See the authoritative guide for the prevention of liver cancer | 2021 version of the primary liver cancer secondary prevention consensus recommended points liver biopsy Xiangya expert consensus liver biopsy as a kind of Diagnosis measures for liver diseases have been used in clinical departments such as liver surgery, transplantation, infection, and gastroenterology for a long time
.
At present, there is no standard, guideline or expert consensus on liver biopsy in China
.
Therefore, the Department of Medical Affairs and Department of Liver Surgery of Xiangya Hospital of Central South University, together with experts from the Department of Hepatology, Ultrasound Imaging, Interventional and Pathology of this hospital, jointly formulated this expert consensus, which aims to provide a reference for clinical liver biopsy
.
Download link: http://guide.
medlive.
cn/guideline/22733 Recommended reading: Liver biopsy: indications, contraindications and methods of operation "Guidelines for the diagnosis and treatment of lenticular degeneration" were refined and revised, which were discussed and written by well-known experts in the field of diagnosis and treatment of hepatolenticular degeneration in China, and were presented at the neurogenetics group meeting of the Chinese Medical Association Neurology Branch.
Discuss on the final draft
.
The content includes the clinical manifestations, diagnosis and differential diagnosis, treatment and prognosis of hepatolenticular degeneration
.
Download link: http://guide.
medlive.
cn/guideline/23083 Recommended reading: How is hepatolenticular degeneration (Wilson disease) diagnosed and treated? The 2021 new version of the guidelines recommends this | Guidelines consensus Guidelines for the treatment of chronic hepatitis B (2020) This guideline is applicable to the grassroots and aims to help general practitioners in the prevention, screening, diagnosis, treatment and treatment of chronic hepatitis B (CHB).
Reasonable decisions are made in long-term follow-up management, but they are not mandatory standards, and it is impossible to include or solve all the problems of CHB management
.
Therefore, when general practitioners diagnose and treat CHB patients, they should fully understand the best clinical evidence for the disease, carefully consider the patient’s specific condition and wishes, and based on their professional knowledge, clinical experience and available medical resources, Develop a comprehensive and reasonable diagnosis and treatment plan
.
We will continue to update and improve this guide based on relevant developments at home and abroad
.
Download link: http://guide.
medlive.
cn/guideline/22842 Recommended reading: "Guidelines for Primary Diagnosis and Treatment of Chronic Hepatitis B (2020)" is released! | Guidelines Consensus 2021 ACG Clinical Guidelines: Diagnosis and Management of Specific Drug-induced Liver Injury In May 2021, the American College of Gastroenterology (ACG) issued guidelines for the diagnosis and management of specific drug-induced liver injury (DILI)
.
DILI refers to liver damage caused by herbal and dietary supplements (HDS) and prescription drugs or over-the-counter drugs.
It is divided into two types: endogenous and specific
.
This article mainly provides guidance and suggestions for the diagnosis and management of specific DILI
.
Download link: http://guide.
medlive.
cn/guideline/23167 Recommended reading: Diagnosis and management of specific drug-induced liver injury: 2021 ACG clinical guidelines released! | Guidelines consensus on the clinical management process of blocking mother-to-child transmission of hepatitis B virus (2021) In order to further standardize the clinical management of the interruption of mother-to-child transmission of HBV in China, the China Hepatitis Prevention Foundation organized experts to compile and publish the "Type B" in 2017 "Clinical Management Process of Maternal and Child Interruption of Hepatitis" (hereinafter referred to as "process")
.
This process has been widely used in clinical practice to block mother-to-child transmission of HBV, and has played a positive role in preventing mother-to-child transmission of HBV
.
In recent years, blocking mother-to-child transmission of HBV has become a hot spot in the field of public health, and relevant research around this hot spot has made remarkable progress
.
We updated the first edition of the "Clinical Management Procedures for Maternal and Child Interruption of Hepatitis B" based on the guidelines or consensus on the prevention of mother-to-child transmission of hepatitis B recently published at home and abroad, in order to update the concept of clinicians and to block HBV.
Provide standardized clinical management of mother-to-child transmission
.
Download link: http://guide.
medlive.
cn/guideline/22863 Recommended reading: update release! Clinical Management Process for Interrupting Mother-to-Child Transmission of Hepatitis B Virus (2021) | Guidelines Consensus 2021 APASL Consensus Guidelines: Management of Drug-induced Liver Injury In February 2021, the Asia-Pacific Society for Liver Research (APASL) issued drug-induced liver injury (DILI) ) Management guide
.
Specific DILI is very similar to acute and chronic liver disease.
Due to the lack of specific diagnostic serological markers and insufficient clinical understanding of it, DILI may develop from asymptomatic to self-limiting disease, and then severe liver damage, leading to acute liver failure
.
This article mainly provides guidance and suggestions for the evaluation, diagnosis and treatment of DILI
.
Recommended reading: Management of Drug-induced Liver Injury: 2021 APASL Consensus Guidelines Released | Guidelines Consensus 2021 AISF/SIN Position Paper: Liver and Kidney Diseases In June 2021, the Italian Society of Liver Diseases (AISF) and the Italian Society of Nephrology (SIN) jointly released the liver Kidney disease submissions
.
Under physiological and pathological conditions, the liver and kidneys are closely connected in an interactive manner
.
This article mainly introduces the latest overview of the correlation between liver and kidney diseases
.
The content involves the diagnosis of kidney damage in patients with chronic liver disease, acute kidney damage from cirrhosis, the relationship between chronic liver disease and chronic kidney disease, the damage to the kidney by liver disease of different etiologies, polycystic kidney disease and liver disease
.
Download link: http://guide.
medlive.
cn/guideline/23466 Recommended reading: Liver cirrhosis and acute kidney injury: understand clearly from 9 aspects! | Guidelines consensus guidelines for primary diagnosis and treatment of chronic hepatitis B (Practical Edition·2020) Hepatitis B virus (HBV) infection is the main cause of chronic liver diseases such as liver cirrhosis and liver cancer
.
It is estimated that the current prevalence of hepatitis B surface antigen (HBsAg) in China is 5%-6%, and there are about 70 million cases of chronic HBV infection, of which 20 million to 30 million are chronic hepatitis B (CHB) patients
.
Although the medical burden caused by HBV-related diseases is very heavy, and the treatment of CHB is constantly evolving, most people with HBV infection are still aware of their own infection status, which has caused some patients to have advanced to the late stage of the disease when they seek medical attention.
.
Therefore, the early screening, diagnosis and follow-up care management of CHB are the key links of prevention and treatment
.
Download link: http://guide.
medlive.
cn/guideline/22964 Recommended reading: "Guidelines for Primary Diagnosis and Treatment of Chronic Hepatitis B (Practical Edition·2020)" is released! | Guidelines Consensus 2021 SMFM Consultation Series #53: Intrahepatic Cholestasis of Pregnancy In February 2021, the Society of Maternal and Fetal Medicine (SMFM) issued a guideline for the management of intrahepatic cholestasis of pregnancy to replace No.
13 in April 2011 File
.
Intrahepatic cholestasis of pregnancy is a liver disease characterized by pruritus and elevated serum bile acid levels.
This article reviews the relevant literature on intrahepatic cholestasis of pregnancy and provides guidance and recommendations based on existing evidence
.
Download link: http://guide.
medlive.
cn/guideline/22404 Recommended reading: Guidelines for the management of intrahepatic cholestasis during pregnancy | Guidelines consensus
Consensus on Level Prevention (2021 Edition)
.
This consensus mainly includes the risk factors, monitoring and screening, early diagnosis and prevention of primary liver cancer in the population of chronic liver disease in China
.
Download link: http://guide.
medlive.
cn/guideline/22780 Recommended reading: See the authoritative guide for the prevention of liver cancer | 2021 version of the primary liver cancer secondary prevention consensus recommended points liver biopsy Xiangya expert consensus liver biopsy as a kind of Diagnosis measures for liver diseases have been used in clinical departments such as liver surgery, transplantation, infection, and gastroenterology for a long time
.
At present, there is no standard, guideline or expert consensus on liver biopsy in China
.
Therefore, the Department of Medical Affairs and Department of Liver Surgery of Xiangya Hospital of Central South University, together with experts from the Department of Hepatology, Ultrasound Imaging, Interventional and Pathology of this hospital, jointly formulated this expert consensus, which aims to provide a reference for clinical liver biopsy
.
Download link: http://guide.
medlive.
cn/guideline/22733 Recommended reading: Liver biopsy: indications, contraindications and methods of operation "Guidelines for the diagnosis and treatment of lenticular degeneration" were refined and revised, which were discussed and written by well-known experts in the field of diagnosis and treatment of hepatolenticular degeneration in China, and were presented at the neurogenetics group meeting of the Chinese Medical Association Neurology Branch.
Discuss on the final draft
.
The content includes the clinical manifestations, diagnosis and differential diagnosis, treatment and prognosis of hepatolenticular degeneration
.
Download link: http://guide.
medlive.
cn/guideline/23083 Recommended reading: How is hepatolenticular degeneration (Wilson disease) diagnosed and treated? The 2021 new version of the guidelines recommends this | Guidelines consensus Guidelines for the treatment of chronic hepatitis B (2020) This guideline is applicable to the grassroots and aims to help general practitioners in the prevention, screening, diagnosis, treatment and treatment of chronic hepatitis B (CHB).
Reasonable decisions are made in long-term follow-up management, but they are not mandatory standards, and it is impossible to include or solve all the problems of CHB management
.
Therefore, when general practitioners diagnose and treat CHB patients, they should fully understand the best clinical evidence for the disease, carefully consider the patient’s specific condition and wishes, and based on their professional knowledge, clinical experience and available medical resources, Develop a comprehensive and reasonable diagnosis and treatment plan
.
We will continue to update and improve this guide based on relevant developments at home and abroad
.
Download link: http://guide.
medlive.
cn/guideline/22842 Recommended reading: "Guidelines for Primary Diagnosis and Treatment of Chronic Hepatitis B (2020)" is released! | Guidelines Consensus 2021 ACG Clinical Guidelines: Diagnosis and Management of Specific Drug-induced Liver Injury In May 2021, the American College of Gastroenterology (ACG) issued guidelines for the diagnosis and management of specific drug-induced liver injury (DILI)
.
DILI refers to liver damage caused by herbal and dietary supplements (HDS) and prescription drugs or over-the-counter drugs.
It is divided into two types: endogenous and specific
.
This article mainly provides guidance and suggestions for the diagnosis and management of specific DILI
.
Download link: http://guide.
medlive.
cn/guideline/23167 Recommended reading: Diagnosis and management of specific drug-induced liver injury: 2021 ACG clinical guidelines released! | Guidelines consensus on the clinical management process of blocking mother-to-child transmission of hepatitis B virus (2021) In order to further standardize the clinical management of the interruption of mother-to-child transmission of HBV in China, the China Hepatitis Prevention Foundation organized experts to compile and publish the "Type B" in 2017 "Clinical Management Process of Maternal and Child Interruption of Hepatitis" (hereinafter referred to as "process")
.
This process has been widely used in clinical practice to block mother-to-child transmission of HBV, and has played a positive role in preventing mother-to-child transmission of HBV
.
In recent years, blocking mother-to-child transmission of HBV has become a hot spot in the field of public health, and relevant research around this hot spot has made remarkable progress
.
We updated the first edition of the "Clinical Management Procedures for Maternal and Child Interruption of Hepatitis B" based on the guidelines or consensus on the prevention of mother-to-child transmission of hepatitis B recently published at home and abroad, in order to update the concept of clinicians and to block HBV.
Provide standardized clinical management of mother-to-child transmission
.
Download link: http://guide.
medlive.
cn/guideline/22863 Recommended reading: update release! Clinical Management Process for Interrupting Mother-to-Child Transmission of Hepatitis B Virus (2021) | Guidelines Consensus 2021 APASL Consensus Guidelines: Management of Drug-induced Liver Injury In February 2021, the Asia-Pacific Society for Liver Research (APASL) issued drug-induced liver injury (DILI) ) Management guide
.
Specific DILI is very similar to acute and chronic liver disease.
Due to the lack of specific diagnostic serological markers and insufficient clinical understanding of it, DILI may develop from asymptomatic to self-limiting disease, and then severe liver damage, leading to acute liver failure
.
This article mainly provides guidance and suggestions for the evaluation, diagnosis and treatment of DILI
.
Recommended reading: Management of Drug-induced Liver Injury: 2021 APASL Consensus Guidelines Released | Guidelines Consensus 2021 AISF/SIN Position Paper: Liver and Kidney Diseases In June 2021, the Italian Society of Liver Diseases (AISF) and the Italian Society of Nephrology (SIN) jointly released the liver Kidney disease submissions
.
Under physiological and pathological conditions, the liver and kidneys are closely connected in an interactive manner
.
This article mainly introduces the latest overview of the correlation between liver and kidney diseases
.
The content involves the diagnosis of kidney damage in patients with chronic liver disease, acute kidney damage from cirrhosis, the relationship between chronic liver disease and chronic kidney disease, the damage to the kidney by liver disease of different etiologies, polycystic kidney disease and liver disease
.
Download link: http://guide.
medlive.
cn/guideline/23466 Recommended reading: Liver cirrhosis and acute kidney injury: understand clearly from 9 aspects! | Guidelines consensus guidelines for primary diagnosis and treatment of chronic hepatitis B (Practical Edition·2020) Hepatitis B virus (HBV) infection is the main cause of chronic liver diseases such as liver cirrhosis and liver cancer
.
It is estimated that the current prevalence of hepatitis B surface antigen (HBsAg) in China is 5%-6%, and there are about 70 million cases of chronic HBV infection, of which 20 million to 30 million are chronic hepatitis B (CHB) patients
.
Although the medical burden caused by HBV-related diseases is very heavy, and the treatment of CHB is constantly evolving, most people with HBV infection are still aware of their own infection status, which has caused some patients to have advanced to the late stage of the disease when they seek medical attention.
.
Therefore, the early screening, diagnosis and follow-up care management of CHB are the key links of prevention and treatment
.
Download link: http://guide.
medlive.
cn/guideline/22964 Recommended reading: "Guidelines for Primary Diagnosis and Treatment of Chronic Hepatitis B (Practical Edition·2020)" is released! | Guidelines Consensus 2021 SMFM Consultation Series #53: Intrahepatic Cholestasis of Pregnancy In February 2021, the Society of Maternal and Fetal Medicine (SMFM) issued a guideline for the management of intrahepatic cholestasis of pregnancy to replace No.
13 in April 2011 File
.
Intrahepatic cholestasis of pregnancy is a liver disease characterized by pruritus and elevated serum bile acid levels.
This article reviews the relevant literature on intrahepatic cholestasis of pregnancy and provides guidance and recommendations based on existing evidence
.
Download link: http://guide.
medlive.
cn/guideline/22404 Recommended reading: Guidelines for the management of intrahepatic cholestasis during pregnancy | Guidelines consensus
